Calibration and Evaluation of Quantitative Antibody Titers for Measles Virus by Using the BioPlex 2200

TF Hatchette, H Scholz, S Bolotin, NS Crowcroft, C Jackson, McLachlan, A Severini and on behalf of the Immunity of Canadians and Risk of Epidemics (iCARE) laboratory group and the Canadian Immunization Research Network (CIRN)

Clin Vaccine Immunol , 2017 Jan; 24(1): e00269-16

The BioPlex 2200 (Bio-Rad Laboratories, Hercules, CA) is a rapid, automated platform, which can screen large numbers of specimens for antibodies to measles, mumps, rubella, and varicella. Although approved for producing qualitative results, in this study we validated the test (off-label) to allow reporting of quantitative results.

To do this, we used the third anti-measles World Health Organization standard to generate a calibration curve that allowed relative fluorescence intensity to be translated into quantitative antibody titer (antibody units [AU]/ml). The results from the BioPlex 2200 and the reference plaque reduction neutralization test (PRNT) exhibited a reasonable correlation following an exponential function, but correlation was poor in low-titer samples. Using a receiver operating characteristics analysis, an equivocal zone for the BioPlex 2200 was established between ≥0.13 and <1.10 AU/ml to achieve 100% specificity (95% confidence interval [CI] = 83.2 to 100%) and 100% sensitivity (95% CI = 93.5 to 100%) versus PRNT. By determining an equivocal range requiring confirmation by PRNT, we can avoid underestimating the levels of immunity through false-negative results and optimize methods for seroepidemiological studies


Leave a Comment

Search Publications